Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 10773 open-label phase IIb study in impaired glucose tolerance and type 2 diabetes mellitus
2010-018708-99Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of empagliflozin in prediabetes and type 2 diabetes mellitus (T2DM) (3 cohorts), sponsored by Boehringer Ingelheim. Started Oct 2010; status: completed.
02
Drugs
empagliflozin
03
Conditions
prediabetestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-018708-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018708-99.